TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06046911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily activity group
Description: The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
Study: NCT05514821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It Sport Shot
Description: Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing \~400mg dietary nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet It Sport Shot
Description: Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing \~400mg dietary nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beet It Sport Shot Placebo
Description: Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing \~ 0 mg dietary nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beet It Sport Shot Placebo
Description: Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing \~ 0 mg dietary nitrate
Study: NCT04746378

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, CSD
Description: Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, CSD
Description: Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, CSD
Description: Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, SA
Description: Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, SA
Description: Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, SA
Description: Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, 3D
Description: Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, 3D
Description: Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, 3D
Description: Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
Study: NCT04140279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprostene Bunod
Description: Ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic solution, no active ingredient.
Study: NCT05515120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG [Xarelto]
Description: It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 300mg
Description: It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acenocoumarol Oral Tablet
Description: It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
Study: NCT05175313

Intervention type: RADIATION
Intervention: transthoracic ultrasonography
Description: 1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound

Intervention type: RADIATION
Intervention: transthoracic ultrasonography
Description: 1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound

Intervention type: RADIATION
Intervention: transthoracic ultrasonography
Description: 1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound

Intervention type: DEVICE
Intervention: spirometry
Description: pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.

Intervention type: DEVICE
Intervention: spirometry
Description: pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.

Intervention type: DEVICE
Intervention: spirometry
Description: pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
Study: NCT04864483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal timing in relation to time of starting the fast
Description: as described

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal timing in relation to time of starting the fast
Description: as described
Study: NCT05917041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAT-001(Software as Medical Device)
Description: Using SAT-001 application for 48 weeks and wearing glasses or not
Study: NCT04980950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science
Description: Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science
Description: Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science
Description: Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science
Description: Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
Study: NCT05117255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy
Description: The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT)
Description: PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
Study: NCT05313126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sterile insect technique (TIS)
Description: Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
Study: NCT05192538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic endoloop pre-test treatment
Description: A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.
Study: NCT05570474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink supplementation
Description: Daily drink containing 20 grams of whey protein, dissolved in 200mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo drink
Study: NCT04691999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: 16-18 hour fasting period four times per week
Study: NCT05097014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF5993
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF1535
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Pressurized metered dose inhaler (pMDI) 2 inhalations bid
Study: NCT05033652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WARNING KD
Description: Within 48h of detecting an abnormal creatinemia value (GFR\<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices.
Study: NCT05794646

Intervention type: OTHER
Group type: OTHER
Intervention: Hybrid effectiveness-implementation study type 2
Description: Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
Study: NCT04444622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: Living bioengineered, non-genetically manipulated, activated Th1-like immune cells differentiated and expanded from precursor cells purified from blood of healthy unrelated donors
Study: NCT05426759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation of epicardial Ganglionated Plexi.
Description: Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
Study: NCT04910503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant
Description: Implant every 4 months if necessary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide Intravitreal Implant
Description: Implantation
Study: NCT05974592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Diabetic Foot Self-Management Training Program will be implemented.
Study: NCT04733781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Lidocaine and Epinephrine
Description: Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Lidocaine and Epinephrine
Description: Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Lidocaine and Epinephrine
Description: Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
Study: NCT05036616

Intervention type: DEVICE
Intervention: Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
Description: Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
Study: NCT05908825

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin C with AHA Exfoliative Serum
Description: Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin C with AHA Exfoliative Serum
Description: Catalyst is a novel skincare product comprised of low concentrations of multiple hydroxy acids and will be randomly assigned as Product A or Product B to be applied to one side of the face.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo serum
Description: Placebo serum will be randomly assigned as Product A or Product B to be applied to one side of the face.
Study: NCT04786951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Training
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based body exposure
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based body exposure
Description: Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Usual cognitive-behavioral treatment (CBT) sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Usual cognitive-behavioral treatment (CBT) sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Usual cognitive-behavioral treatment (CBT) sessions.
Study: NCT04572022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step wise post-procedure mobile health shared rehabilitation teaching video instructions modules (as per fracture type)
Description: Intervention group receive proximal humerus fracture standard care with additional mobile health shared step-wise rehabilitation teaching video instructions modules (as per fracture type). Classic Blue tooth technology will be utilized for teaching information sharing from doctor to the patient.
Study: NCT04894162

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
Study: NCT05279209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed sclerotherapy
Description: Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection
Description: Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.
Study: NCT05908955

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: pulmonary vein isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI+ quantitative SVCI
Description: pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
Study: NCT04895072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a standard injection rate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long group
Description: Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a long injection rate.
Study: NCT06262854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium-sulphate granules with tobramicina+vancomicina
Description: Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Calcium-sulphate granules with tobramicina+vancomicina
Description: Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis
Study: NCT05877222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 10 mg
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
Study: NCT05235399

Intervention type: OTHER
Intervention: Echo scans
Description: Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
Study: NCT05912803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Equestrian Therapy
Description: The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuro-Motor Therapy
Description: This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
Study: NCT05241782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks
Study: NCT05992623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll external defibrillator
Description: Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll external defibrillator
Description: Patients with AF will be randomized to receive a full output synchronized 200J shock using a RBW waveform from a Zoll defibrillator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lifepak external defibrillator
Description: Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lifepak external defibrillator
Description: Patients with AF will be randomized to receive a full output synchronized 360J shock using a BTE waveform from a Lifepak defibrillator
Study: NCT05397496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIT565
Description: Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIT565
Description: Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIT565
Description: Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIT565
Description: Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIT565
Description: Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection
Study: NCT06558227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 for Injection
Description: 10 mg/kg or 20 mg/kg administered intravenously Q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG005 for Injection
Description: 10 mg/kg or 20 mg/kg administered intravenously Q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered intravenously Q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered intravenously Q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg administered intravenously Q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered intravenously Q3w